Assertion Supported AI assessment confidence: 95% certainty 4/5 debate potential 2/5

Andy Tran: Gene Editing Enables Curative Single-Dose Treatments

Andy Tran · CRISPR 2.0 and the Future of Gene Therapies · Oct 5, 2019 · at 1:24

Andy Tran, Deal Partner on the a16z bio investing team, discusses how cell and gene therapies differ fundamentally from traditional small molecule and antibody therapeutics.

0:00 / 0:12exact quote · 12.9s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“Of course, this is certainly a big paradigm shift and very exciting as these technologies have given us the power to precisely target And eliminate the origin of disease, as well as be very curative with just a single dose of the drug.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Modern gene editing and cell therapy technologies enable precise targeting and elimination of the genetic origin of disease, providing curative outcomes with a single dose.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

The claim stated that modern gene editing and cell therapy technologies enable precise targeting and elimination of the genetic origin of disease, providing curative outcomes with a single dose. By the evaluation horizon of October 5, 2022, multiple FDA approvals and peer-reviewed clinical trial publications had demonstrated single-dose gene therapies and gene-editing treatments achieving functional curative outcomes for genetic diseases.

FDA approved Zolgensma in May 2019 as a single-dose AAV gene therapy for spinal muscular atrophy (SMA).
FDA approved Zynteglo in August 2022 as a single-dose ex vivo gene therapy achieving transfusion independence in 89% of patients with beta-thalassemia.
A December 2020 NEJM study (Frangoul et al.) published clinical trial data showing single-dose CRISPR/Cas9 gene editing (CTX001) eliminated painful crises in severe sickle cell disease and eliminated transfusions in beta-thalassemia.
A June 2021 NEJM study (Gillmore et al.) showed single-dose in vivo CRISPR/Cas9 editing (NTLA-2001) reduced disease-causing TTR protein levels by up to 96% in hereditary transthyretin amyloidosis.

Checked against

[1] childrenshospital.org [2] drugtimes.cn [3] drugs.com [4] fda.gov [5] curesma.org [6] novartis.com [7] fda.gov [8] drugs.com

CRISPR Cas9 gene editing clinical trial single dose NEJM 2020 2021 Zolgensma FDA approval date single dose FDA approved single dose gene therapy before October 2022 Zynteglo FDA approval date 2022 "Frangoul" "Sickle Cell" "NEJM" 2021 "Gillmore" "Transthyretin" "NEJM" 2021 Skysona FDA approval date 2022 single dose

assessed as of 2026-07-28

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

disease origin gene editing technologies

⚑ Spot an error? Report it

More from Andy Tran

Prediction Not checkable as stated

Tran predicts 10 to 20 gene therapy approvals annually by 2030

“We're expecting at least 10 to 20 gene therapy approvals per year by the end of the decade.”

Andy Tran Oct 5, 2019 ▶ 2:23 CRISPR 2.0 and the Future of Gene Therapies

Insight

Tran: CRISPR is evolving into a cellular search engine platform

“Instead of just this pair of molecular scissors that everyone talks about, the biggest recent shift in the field is this push towards making CRISPR a search engine platform of the cell.”

Andy Tran Oct 5, 2019 ▶ 6:21 CRISPR 2.0 and the Future of Gene Therapies

Insight

Andy Tran: Gene therapy winners will pair platforms with disease-specific optimization

“Regardless of the type of vector that you're engineering, we believe the winners in the space are the ones that could harness a specific platform and marry it with very thoughtful optimization towards specific disease areas.”

Andy Tran Oct 5, 2019 ▶ 14:55 CRISPR 2.0 and the Future of Gene Therapies

Prediction Not checkable as stated

Tran: Metagenomic mining will uncover genome editing systems beyond CRISPR

“As we continue to mine new metagenomic data of new species, it's not crazy to think that perhaps even CRISPR itself is by no means the final frontier of genome engineering.”

Andy Tran Oct 5, 2019 ▶ 18:46 CRISPR 2.0 and the Future of Gene Therapies

Opinion

Tran: Manufacturing is an overlooked existential threat to gene therapy

“So once you've designed the perfect gene therapy, perhaps one of the most overlooked, but most existential threats to the industry is challenges in manufacturing.”

Andy Tran Oct 5, 2019 ▶ 19:23 CRISPR 2.0 and the Future of Gene Therapies

Insight

Tran: Simple CRISPR knockouts often outperform complex new genome engineering tools

“Many times, the latest, most advanced, mechanistically complex, and by definition least validated system is not the best tool if a simple CRISPR knockout, for instance, can solve your problem.”

Andy Tran Oct 5, 2019 ▶ 23:31 CRISPR 2.0 and the Future of Gene Therapies

Andy Tran: Gene Editing Enables Curative Single-Dose Treatments

More from Andy Tran

Turn any episode into a week of clips.